Mounjaro Dethrones Augmentin in India's Drug Market
Eli Lilly's weight-loss injection Mounjaro has replaced Augmentin, a long-time bestseller, in India's pharmaceutical market. Urban buyers are chasing the newer GLP-1 drug despite its price, creating a sharp boom in demand for this class of medicines. The shift is changing the economics of the sector.
Context
Mounjaro's active ingredient is tirzepatide, a GLP-1 drug that mimics a gut hormone to lower blood sugar and curb appetite. Augmentin is a widely used antibiotic, so the switch shows how demand for diabetes and weight-loss drugs is reshaping India's pharma market.
Burning Potato score: 58%